Aclaris Therapeutics Inc (ACRS)
1.18
-0.04
(-3.28%)
USD |
NASDAQ |
Apr 24, 16:00
1.18
0.00 (0.00%)
After-Hours: 20:00
Aclaris Therapeutics Enterprise Value: -32.58M for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 23, 2024 | -32.58M |
April 22, 2024 | -32.58M |
April 19, 2024 | -31.16M |
April 18, 2024 | -31.87M |
April 17, 2024 | -31.87M |
April 16, 2024 | -32.58M |
April 15, 2024 | -33.29M |
April 12, 2024 | -33.29M |
April 11, 2024 | -32.58M |
April 10, 2024 | -36.83M |
April 09, 2024 | -34.71M |
April 08, 2024 | -34.71M |
April 05, 2024 | -34.71M |
April 04, 2024 | -31.87M |
April 03, 2024 | -30.45M |
April 02, 2024 | -32.58M |
April 01, 2024 | -29.74M |
March 28, 2024 | -31.16M |
March 27, 2024 | -29.74M |
March 26, 2024 | -35.41M |
March 25, 2024 | -36.83M |
March 22, 2024 | -37.54M |
March 21, 2024 | -34.00M |
March 20, 2024 | -34.71M |
March 19, 2024 | -37.54M |
Date | Value |
---|---|
March 18, 2024 | -37.54M |
March 15, 2024 | -36.12M |
March 14, 2024 | -37.54M |
March 13, 2024 | -30.45M |
March 12, 2024 | -32.58M |
March 11, 2024 | -27.61M |
March 08, 2024 | -19.10M |
March 07, 2024 | -23.36M |
March 06, 2024 | -16.97M |
March 05, 2024 | -29.03M |
March 04, 2024 | -30.45M |
March 01, 2024 | -31.16M |
February 29, 2024 | -34.71M |
February 28, 2024 | -34.71M |
February 27, 2024 | -34.00M |
February 26, 2024 | -33.29M |
February 23, 2024 | -34.71M |
February 22, 2024 | -33.29M |
February 21, 2024 | -34.00M |
February 20, 2024 | -33.29M |
February 16, 2024 | -34.71M |
February 15, 2024 | -31.87M |
February 14, 2024 | -32.58M |
February 13, 2024 | -36.12M |
February 12, 2024 | -31.87M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-57.37M
Minimum
Nov 13 2023
1.424B
Maximum
Apr 07 2021
419.41M
Average
414.72M
Median
Sep 06 2023
Enterprise Value Benchmarks
Aldeyra Therapeutics Inc | 102.61M |
Akoya Biosciences Inc | 179.36M |
MSP Recovery Inc | 1.832B |
Bullfrog AI Holdings Inc | 20.14M |
Cadrenal Therapeutics Inc | -1.575M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -1.491M |
Revenue (Quarterly) | 17.57M |
Total Expenses (Quarterly) | 41.29M |
EPS Diluted (Quarterly) | -0.02 |
Gross Profit Margin (Quarterly) | 63.41% |
Profit Margin (Quarterly) | -8.49% |
Earnings Yield | -107.6% |
Normalized Earnings Yield | -130.35 |